Accuray Inc. (NASDAQ:ARAY) traded down 3.7% during trading on Thursday . The company traded as low as $4.90 and last traded at $4.90, with a volume of 288,689 shares trading hands. The stock had previously closed at $5.09.

Several brokerages recently issued reports on ARAY. Brean Capital reissued a “buy” rating and set a $12.00 target price on shares of Accuray in a research note on Sunday, May 22nd. Morgan Stanley reissued a “hold” rating on shares of Accuray in a research note on Wednesday, April 27th. Finally, Zacks Investment Research lowered shares of Accuray from a “buy” rating to a “hold” rating in a research note on Monday, April 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. Accuray presently has a consensus rating of “Hold” and an average price target of $8.58.

The firm’s market cap is $396.53 million. The firm’s 50-day moving average price is $5.25 and its 200-day moving average price is $5.57.

Accuray (NASDAQ:ARAY) last posted its quarterly earnings results on Tuesday, April 26th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.07. During the same period last year, the business posted ($0.04) earnings per share. The business had revenue of $105.30 million for the quarter, compared to analysts’ expectations of $102.79 million. The company’s revenue was up 8.0% compared to the same quarter last year. On average, equities research analysts anticipate that Accuray Inc. will post ($0.27) EPS for the current fiscal year.

Several hedge funds and institutional investors have bought and sold shares of the company. Lapides Asset Management LLC increased its position in Accuray by 1.8% in the fourth quarter. Lapides Asset Management LLC now owns 2,149,500 shares of the company’s stock valued at $14,509,000 after buying an additional 38,600 shares during the period. Wells Fargo & Company MN increased its position in Accuray by 20.9% in the fourth quarter. Wells Fargo & Company MN now owns 1,656,069 shares of the company’s stock valued at $11,178,000 after buying an additional 286,458 shares during the period. Boston Partners increased its position in Accuray by 10.8% in the fourth quarter. Boston Partners now owns 4,272,040 shares of the company’s stock valued at $28,836,000 after buying an additional 417,568 shares during the period. Neuberger Berman Group LLC increased its position in Accuray by 16.0% in the fourth quarter. Neuberger Berman Group LLC now owns 2,800,295 shares of the company’s stock valued at $18,902,000 after buying an additional 385,220 shares during the period. Finally, Russell Frank Co increased its position in Accuray by 24.0% in the fourth quarter. Russell Frank Co now owns 1,028,628 shares of the company’s stock valued at $7,077,000 after buying an additional 198,874 shares during the period.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.